Zur Startseite von DrArbeit.de,
der deutschlandweiten Stellenbörse für Diplomarbeiten und Doktorarbeiten


Archiv - Stellenangebot


Dies ist ein Angebot aus der Datenbank von DrArbeit.de

Um die Datenbank komfortabel nach weiteren Angeboten durchsuchen zu können, klicken Sie einfach oben oder hier.

Archiv-Übersicht     Angebot Nr. 13380

Angebotsdatum: 12. April 2019
Art der Stelle: Doktorarbeit
Fachgebiet: Physik > Angewandte Physik
Titel des Themas: Radioproteomics to Evaluate the Individual Radiation Resistance in Patients with Primary Prostate Carcinoma

Institut: University Medical Center Freiburg
Prof. Michael Bock
Killianstr. 5a
79106 Freiburg
Tel.: +49 761 27094140   Fax.:
Bundesland: Baden-Württemberg
Homepage: http://www.uniklinik-freiburg.de/mr
E-Mail Kontakt: mail

Beschreibung: In Germany, about one quarter of all newly diagnosed tumors in men are found in the prostate, and annually about 58.000 men receive the diagnosis of a prostate carcinoma (PCa). Every year, 12.000 patients with a PCa die of the consequences of the disease. One therapy option for PCa is radiation therapy (RT), but the outcome of RT varies tremendously as the PCa can exhibit a large variation in radiation resistance.
In this PhD project, new image and data analysis methods will be developed to predict the outcome of a RT in PCa patients based on multi-modality clinical imaging data and biological and histological information. A post-processing pipeline using novel artificial intelligence methods (e.g., convolutional neural networks) will be established using existing patient data for training. Furthermore, concepts for the integration of heterogeneous input data (images, proteomics, etc.) will be developed and tested with the aim to quantify and predict radiation resistance in all areas of the tumor.
Methoden: The highly interdisciplinary work will be conducted at the Dept. of Radiology – Medical Physics (Prof. M. Bock) in close cooperation with the Depts. of Radiation Oncology (Dr. C. Zamboglou), Urology (Dr. K. Reichel) and Pathology (Prof. O. Schilling). The work includes the design, programming and testing of a post-processing algorithm using high-level programming environments (e.g., MatLab from MathWorks), and interaction with all clinical partners of the research consortium.

The successful candidate should have an interest and initial experience/background in:
- Computer programming (preferably in MatLab, and C++)
- Image processing
- Convolutional Neural Networks
We offer:
- An interdisciplinary dynamic research environment
- State-of-the-art computer equipment
- High-level support from MathWorks
The starting date is negotiable.
Anfangsdatum: 12. April 2019
Geschätzte Dauer: 36 months
Bezahlung: 65% of TVL E13
Papers: MRI versus ⁶⁸Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer. Zamboglou C*, Wieser G*, Hennies S, Rempel I, Kirste S, Soschynski M, Rischke HC, Fechter T, Jilg CA, Langer M, Meyer PT, Bock M, Grosu AL. Eur J Nucl Med Mol Imaging. 2016 May;43(5):889-97. doi: 10.1007/s00259-015-3257-5.

(68)Ga-HBED-CC-PSMA PET/CT Versus Histopathology in Primary Localized Prostate Cancer: A Voxel-Wise Comparison. Zamboglou C*, Schiller F*, Fechter T, Wieser G, Jilg CA, Chirindel A, Salman N, Drendel V, Werner M, Mix M, Meyer PT, Grosu AL. Theranostics. 2016 Jun 18;6(10):1619-28. doi: 10.7150/thno.15344.

Comparison of 68Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology. Zamboglou C, Drendel V, Jilg CA, Rischke HC, Beck TI, Schultze-Seemann W, Krauss T, Mix M, Schiller F, Wetterauer U, Werner M, Langer M, Bock M, Meyer PT, Grosu AL. Theranostics. 2017 Jan 1;7(1):228-237. doi: 10.7150/thno.16638.

Single fraction multimodal image guided focal salvage high-dose-rate brachytherapy for recurrent prostate cancer. Zamboglou C, Rischke HC, Meyer PT, Knobe S, Volgeova-Neher N, Kollefrath M, Jilg CA, Grosu AL, Baltas D, Kroenig M. J Contemp Brachytherapy. 2016 Jun;8(3):241-8. doi: 10.5114/jcb.2016.61067.

The dose distribution in dominant intraprostatic tumour lesions defined by multiparametric MRI and PSMA PET/CT correlates with the outcome in patients treated with primary radiation therapy for prostate cancer. Zamboglou C*, Klein CM*, Thomann B, Fassbender TF, Rischke HC, Kirste S, Henne K, Volegova-Neher N, Bock M, Langer M, Meyer PT, Baltas D, Grosu AL. Radiat Oncol. 2018 Apr 12;13(1):65. doi: 10.1186/s13014-018-1014-1.

Evaluation of intensity modulated radiation therapy dose painting for localized prostate cancer using 68Ga-HBED-CC PSMA-PET/CT: A planning study based on histopathology reference. Zamboglou C, Sachpazidis I, Koubar K, Drendel V, Wiehle R, Kirste S, Mix M, Schiller F, Mavroidis P, Meyer PT, Werner M, Grosu AL, Baltas D. Radiother Oncol. 2017 Jun;123(3):472-477. doi: 10.1016/j.radonc.2017.04.021.

Focal dose escalation for prostate cancer using 68Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference. Zamboglou C, Thomann B, Koubar K, Bronsert P, Krauss T, Rischke HC, Sachpazidis I, Drendel V, Salman N, Reichel K, Jilg CA, Werner M, Meyer PT, Bock M, Baltas D, Grosu AL. Radiat Oncol. 2018 May 2;13(1):81. doi: 10.1186/s13014-018-1036-8.

Outcome after PSMA PET/CT based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy – a bi-institutional retrospective analysis. Schmidt-Hegemann NS, Stief C, Kim TH, Eze C, Kirste S, Strouthos I, Li M, Schultze-Seemann W, Ilhan H, Fendler WP, Bartenstein P, Ganswindt U, Belka C, Grosu AL, Meyer PT, Zamboglou C. J Nucl Med. 2018 Jul 12. pii: jnumed.118.212563. doi: 10.2967/jnumed.118.212563.

Influence of inhomogeneous radiosensitivity distributions and intrafractional organ movement on the tumour control probability of focused IMRT in prostate cancer. Thomann B, Sachpazidis I, Koubar K, Zamboglou C, Mavroidis P, Wiehle R, Grosu AL, Baltas D. Radiother Oncol. 2018 Apr;127(1):62-67. doi: 10.1016/j.radonc.2018.02.006. Epub 2018 Mar 13.

Proteome Profiling of Primary Pancreatic Ductal Adenocarcinomas Undergoing Additive Chemoradiation Link ALDH1A1 to Early Local Recurrence and Chemoradiation Resistance.Oria VO, Bronsert P, Thomsen AR, Föll MC, Zamboglou C, Hannibal L, Behringer S, Biniossek ML, Schreiber C, Grosu AL, Bolm L, Rades D, Keck T, Werner M, Wellner UF, Schilling O. Transl Oncol. 2018 Dec;11(6):1307-1322. doi: 10.1016/j.tranon.2018.08.001.
Sonstiges: This work is funded by the Klaus-Tschira-Foundation.